Use of analgesics in older individuals with special emphasis on organ failures: pitfalls and caveats
Authors:
- Asli Bahar UcarAsli Bahar Ucar
- Mehmet UnaldiMUMehmet Unaldi
- Neslihan KaytuogluNKNeslihan Kaytuoglu
- Busra ErdemBEBusra Erdem
- Bilgen OzkayaBOBilgen Ozkaya
- Sezin BozkurtSBSezin Bozkurt
- Pinar VargunPVPinar Vargun
- Sennaz SahinSSSennaz Sahin
- Mehmet Can GirginMGMehmet Can Girgin
- Talha CiftciTCTalha Ciftci
- Ozgur KarciogluOKOzgur Karcioglu
Open Access
- 1 September 2026
- journal article
- review article
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 126
Abstract
Pain in older adults is highly prevalent and persistently undertreated, and its management becomes substantially more hazardous when renal, hepatic, or respiratory failure co-exists. Age-related pharmacokinetic changes — reduced hepatic blood flow and cytochrome P450 activity, declining glomerular filtration, and altered body composition — are compounded by pharmacodynamic changes, including heightened central nervous system sensitivity and reduced homeostatic reserve. This narrative review synthesises contemporary evidence and current prescribing frameworks into an organ-failure-stratified approach to analgesic selection. Paracetamol and topical agents remain the safest first-line options across all three organ failure states. Non-steroidal anti-inflammatory drugs should be avoided when the estimated glomerular filtration rate falls below 30 mL/min and are contraindicated in cirrhosis. Opioids remain indispensable for moderate-to-severe pain but require dose reduction, interval extension, and close monitoring: fentanyl and buprenorphine are preferred in renal failure, whereas morphine, codeine, and meperidine should be avoided; all opioid doses must be reduced in hepatic failure; and in respiratory failure or chronic obstructive pulmonary disease opioids should be given at the lowest effective dose and never combined with other central nervous system depressants. Adjuvant analgesics carry agent-specific organ restrictions. Frailty, cognitive impairment, and polypharmacy further modify risk. ‘Start low, go slow’ must be calibrated individually to the type and severity of organ dysfunction present.Keywords
This publication has 42 references indexed in Scilit:
- Pain management in the perioperative orthogeriatric setting: Recommendations of the special interest group Orthogeriatrics of the German Geriatrics SocietyZeitschrift für Gerontologie und Geriatrie, 2026
- Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort studySupportive Care in Cancer, 2026
- Opioid use in patients aged 90 years or older with terminal cancer in a palliative care unit: a single-center retrospective observational studySupportive Care in Cancer, 2025
- Pain Control in the Older Person2025
- Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A ReviewClinical Pharmacokinetics, 2025
- IV ketamine infusion therapy for chronic pain: A systematic review and meta‐analysisMedicine Advances, 2023
- Must-Known Special Considerations for Acute Pain Management in Geriatric Patient Population2023
- Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and ToxicityCurrent Pain and Headache Reports, 2021
- Opioids for Chronic Noncancer PainJAMA, 2018
- Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM)Drugs & Aging, 2018